NeuroVive Pharmaceutical AB Interim report January - June 2018
(WorldNews Sweden)

NeuroVive Pharmaceutical AB Interim report January - June 2018 NeuroVive out-licenses targeted LHON therapy to BridgeBio Important events January-June 2018 NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma`s new subsidiary Fortify Therapeutics. The agreement has a total potential value of approximately $60 million USD including any royalties. NeuroVive conducts a preferential rights issue. NeuroVive and Yungjin reports positive KL1333 phase I clinical study results paving the way for further clinical...